TH103
Phase 1- Indications
- Neovascular age-related macular degeneration (nAMD)
Company intelligence / Profile preview
AlloVir
Waltham, Massachusetts, United Statesallovir.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 1
01
Overview
The company faced significant setbacks in December 2023 when it abandoned three late-stage trials of its lead asset, causing shares to plunge 64%[7]. Previously had positive Phase 2 proof-of-concept data for lead program Viralym-M published in Journal of Clinical Oncology[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Allogeneic T-cell therapiesMulti-virus specific T cell (VST) therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Baylor College of Medicine's Center for Cell and Gene Therapy
Beyond the preview
Go deeper on AlloVir.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloVir.